FDA approval of imatinib drug for the treatment of different types of cancers by the major players propelling the growth of the imatinib drug market. For instance, in July 2019, Lupin Ltd. announced the launch of Imatinib Mesylate tablets, 100mg (base) and 400 mg (base). Lupin alliance partner Natco had received approval from the US FDA earlier. Lupin’s Imatinib Mesylate Tablet, 100 mg (base) and 400 mg (base) is the generic version of Novartis Pharmaceuticals Corp’s Gleevec tablets 100mg and 400 mg.
To Request a Sample of our Report on Imatinib Drug Market: https://www.omrglobal.com/request-sample/imatinib-drug-market
In October 2018, Dr. Reddy’s Laboratories, Ltd. announced the launch of its Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version Gleevec tablets in the United States market for the treatment of different types of cancer. Imatinib Mesylate is a US FDA approved drug for commercial sale in the US which is expected to boost the imatinib market in the country. Imatinib Mesylate tablets are available in two different strengths i.e. 100 mg and 400 mg.
In September 2017, Mylan N.V. announced the US launch of Imatinib Mesylate Tablets in 100 mg and 400 mg generic version. Mylan received final approval from the U.S Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Imatinib Mesylate tablets can be used for multiple indications including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES) and aggressive systemic mastocytosis (ASM).
(Get 15% Discount on Buying this Report)
A full Report of Imatinib Drug Market is Available at: https://www.omrglobal.com/industry-reports/imatinib-drug-market
Imatinib Drug Market Segmentation
By Drug Form
- Tablet
- Capsule
By Application
- Blood Cancer (Leukemia and Other Blood Cancers)
- Gastrointestinal Stromal Tumors (GIST)
- Skin Tumors (Dermatofibrosarcoma Protuberans)
- Other Tumors (Systemic Mastocytosis)
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
